
RELIEF CLOSES CHF 10M PRIVATE PLACEMENT: THE ADVISORS

Posted on 24 March 2021



Category: Capital Markets

Tags: Christian Leuenberger, Christian Schneiter, Ex-Featured, Manu Ferro, Pestalozzi, Peter Kühn, Robert Bernet,

Severin Roelli, Vischer



RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM (Aviptadil) in advanced clinical development to treat severe COVID-19 patients, has.entered.into.a.binding.agreement with a single healthcare-dedicated U.S. institutional investor to purchase in a private placement Relief shares of CHF 10m, to be delivered from Relief's treasury shares that were issued out of its authorized share capital under exclusion of the existing shareholders' pre-emptive rights. The transaction closed on 18 March 2021. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The advisors

VISCHER <u>advised Relief regarding the Swiss legal aspects of this transaction</u> with Akerman LLP advising on U.S. laws. The team led by partner Dr. Robert Bernet (Corporate/M&A - pictured right) comprised Dr. Peter Kühn (Counsel, Corporate/M&A) and Christian Schneiter (Associate, Banking & Finance).

Pestalozzi advised H.C. Wainwright. The team <u>included</u> Christian Leuenberger (Lead Partner - Capital Markets, Corporate/M&A - pictured left), Severin Roelli (Partner - Corpoarte/M&A), Manu Ferro (Associate - Banking & Finance).